| ²é¿´: 475 | »Ø¸´: 2 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
wqssfj1Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóÖú·Ò룡£¡£¡
|
|
| Since the IR formulation showed a considerable decrease in plasma exposure with food and high peak-to-trough fluctuations in plasma concentrations with once daily dosing, a modified release tablet using Astellas¡¯Oral Controlled Absorption System (OCAS) was developed for use in the clinical development program and subsequent commercialization. |
» ²ÂÄãϲ»¶
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ4È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ4È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ5È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ5È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ10È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
cean
½ð³æ (Ö°Òµ×÷¼Ò)
ŒÅÉþÒ»Ìõ
- ·ÒëEPI: 41
- Ó¦Öú: 23 (СѧÉú)
- ½ð±Ò: 53.1
- É¢½ð: 2045
- ºì»¨: 2
- Ìû×Ó: 3442
- ÔÚÏß: 578.8Сʱ
- ³æºÅ: 1147499
- ×¢²á: 2010-11-15
- רҵ: ¹«¹²¹ØÏµÑ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
sltmac: ½ð±Ò+1 2012-08-14 07:55:41
sltmac: ½ð±Ò+5 2012-09-21 08:24:20
sltmac: ·ÒëEPI+1 2012-09-21 08:24:27
sltmac: ½ð±Ò+1 2012-08-14 07:55:41
sltmac: ½ð±Ò+5 2012-09-21 08:24:20
sltmac: ·ÒëEPI+1 2012-09-21 08:24:27
| irµÄÐγɱíÃ÷ÁËѪ½¬ºÍʳƷ½Ó´¥£¨Ê±¼ä£©¼±¾çËõ¶Ì£¬ÔÚÿÌì¼ÓÒ©Ò»´ÎµÄÇé¿öÏÂѪ½¬Å¨¶È³ÊÏָߵķå-¹È²¨¶¯£¬Òò´ËÀûÓÃocas¿ª·¢Á˿ɵ÷ÊÍ·ÅҩƬ£¬ÓÃÓÚÁÙ´²ÊÔÑéºÍËæºóµÄÉÌÒµ»¯¡£ |

2Â¥2012-08-13 21:00:02
wqssfj1
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 1
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 5947.4
- É¢½ð: 21
- ºì»¨: 3
- Ìû×Ó: 1448
- ÔÚÏß: 252.5Сʱ
- ³æºÅ: 1391164
- ×¢²á: 2011-09-05
- רҵ: Ò©Îï×ÊÔ´
3Â¥2012-08-14 08:25:04













»Ø¸´´ËÂ¥